Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
icon
Us company
Asset icon - trade crypto, stocks, and gold on Pluang

Buy & Sell TG Therapeutics Inc (TGTX) – TG Therapeutics Inc Price Today

24H
1W
1M
3M
YTD
1Y
5Y

Aura AI Summary

TG Therapeutics (TGTX) trades at $39.48, showing slight daily weakness but maintaining a bullish technical signal. The company reported strong revenue growth driven by its Briumvi MS drug, with 2025 revenue reaching $616M and net income of $447M. Recent Q1 2026 earnings missed expectations, but the company raised its full-year 2026 revenue guidance to approximately $925M, reflecting confidence in its core product's performance.
The outlook is positive based on strong revenue growth and raised guidance, supported by a bullish analyst consensus. Key risks include recent earnings misses and competitive pressures in the MS treatment market. The stock's valuation appears reasonable with a P/E of 13.8, but high P/B and EV/EBITDA ratios suggest premium pricing relative to assets and operating earnings.
Read full analysis

Key Stats

  • Market Cap
    $6.04B
  • Sector
    Health
  • 3M Drawdown
    -12.82%
  • Enterprise Value
    $6.28B
  • Dividend Yield
    -
  • Trading Activity
    8% Buy | 92% Sell
  • Typical Hold Time
    8 days
$39.1
52W Low: $26.39
11 Aug 2025
52W High: $43.14
11 May 2026

TG Therapeutics Inc (TGTX) is currently valued at a market capitalization of $6.04B, with an enterprise value of $6.28B. Over the past 52 weeks, TG Therapeutics Inc has traded between a low of $26.39 and a high of $43.14, highlighting its annual price range. Over the past three months, TG Therapeutics Inc has recorded a drawdown of -12.82%, reflecting recent price volatility. On average, investors hold TG Therapeutics Inc for approximately 8 days, indicating typical investor behavior on the platform.

About TG Therapeutics Inc

TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.



People also bought


Global US Market Prices


Frequently Asked Questions

US stocks trading hours: Monday - Friday (Except for US public holidays) Time: 21.30 - 04.00 WIB 20.30 - 03.00 WIB (Daylight Savings Time*) *The next Daylight Savings is scheduled to begin on March 13, 2022 and ends on November 6, 2022. You can place limit orders outside of the trading hours, but it can only be executed during trading hours. For illustration, a stock is currently trading at $10 per share, but you only want to pay $7 per share at most. Let’s say you set your limit price to $7 at 18.00. Your order will be executed when the market is open at 21.30 if the stock drops from $10 to $7 or lower. Similarly, if the stock price doesn’t drop to $7, your order won’t be executed.
Yes, you are eligible to receive dividend payment if and when the company pays them on one condition: minimum net dividend paid is at least $0.01. Net dividend is gross dividend subtracted by 15% withholding tax.
Yes, it is. US Stocks risk is managed by PT PG Berjangka which is licensed by Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by Jakarta Futures Exchange (JFX) and Indonesian Clearing House (KBI).
Pluang charges a fixed transaction fee of 0.30% for regular users and 0.20% for Pluang Plus members, including VAT to cover the exchange fees and operational costs.

Key Stats

  • Market Cap
    $6.04B
  • Sector
    Health
  • 3M Drawdown
    -12.82%
  • Enterprise Value
    $6.28B
  • Dividend Yield
    -
  • Trading Activity
    8% Buy | 92% Sell
  • Typical Hold Time
    8 days
$39.1
52W Low: $26.39
11 Aug 2025
52W High: $43.14
11 May 2026

TG Therapeutics Inc (TGTX) is currently valued at a market capitalization of $6.04B, with an enterprise value of $6.28B. Over the past 52 weeks, TG Therapeutics Inc has traded between a low of $26.39 and a high of $43.14, highlighting its annual price range. Over the past three months, TG Therapeutics Inc has recorded a drawdown of -12.82%, reflecting recent price volatility. On average, investors hold TG Therapeutics Inc for approximately 8 days, indicating typical investor behavior on the platform.

Let’s invest in this asset by signing up or download!